Correlation Between Bio Path and Endonovo Therapeutics
Can any of the company-specific risk be diversified away by investing in both Bio Path and Endonovo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bio Path and Endonovo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bio Path Holdings and Endonovo Therapeutics, you can compare the effects of market volatilities on Bio Path and Endonovo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bio Path with a short position of Endonovo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bio Path and Endonovo Therapeutics.
Diversification Opportunities for Bio Path and Endonovo Therapeutics
0.08 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Bio and Endonovo is 0.08. Overlapping area represents the amount of risk that can be diversified away by holding Bio Path Holdings and Endonovo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Endonovo Therapeutics and Bio Path is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bio Path Holdings are associated (or correlated) with Endonovo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Endonovo Therapeutics has no effect on the direction of Bio Path i.e., Bio Path and Endonovo Therapeutics go up and down completely randomly.
Pair Corralation between Bio Path and Endonovo Therapeutics
Given the investment horizon of 90 days Bio Path Holdings is expected to under-perform the Endonovo Therapeutics. But the otc stock apears to be less risky and, when comparing its historical volatility, Bio Path Holdings is 2.33 times less risky than Endonovo Therapeutics. The otc stock trades about -0.17 of its potential returns per unit of risk. The Endonovo Therapeutics is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest 0.04 in Endonovo Therapeutics on December 20, 2024 and sell it today you would lose (0.02) from holding Endonovo Therapeutics or give up 50.0% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 71.19% |
Values | Daily Returns |
Bio Path Holdings vs. Endonovo Therapeutics
Performance |
Timeline |
Bio Path Holdings |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Endonovo Therapeutics |
Bio Path and Endonovo Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Bio Path and Endonovo Therapeutics
The main advantage of trading using opposite Bio Path and Endonovo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bio Path position performs unexpectedly, Endonovo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endonovo Therapeutics will offset losses from the drop in Endonovo Therapeutics' long position.Bio Path vs. Capricor Therapeutics | Bio Path vs. NextCure | Bio Path vs. Pulmatrix | Bio Path vs. Crinetics Pharmaceuticals |
Endonovo Therapeutics vs. Cingulate | Endonovo Therapeutics vs. Purple Biotech | Endonovo Therapeutics vs. Soleno Therapeutics | Endonovo Therapeutics vs. Genelux Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |